VigRX Plus is the result of collaboration between herbal scientists, medical consultants, and nutraceutical engineers.

Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic ...

The Digital Health Awards celebrates the best digital health resources developed for consumers and healthcare professionals. Visory Health was recognized as a digital resource that is redefining ...

The groundbreaking study delivers unprecedented insight into how AI influences the reputation of the 50 most prominent OTC brands across ten major product categories. CeraVe came out as the leading ...

In addition, the Company has granted the underwriter a 45-day option to purchase up to 180,000 additional shares of common stock and/or 180,000 Common Warrants, solely to cover over-allotments, if any ...

With the major structural changes largely behind it, Trinity Biotech is now concentrating on fine-tuning its global operations, leveraging its new foundation to unlock further efficiencies and EBITDA ...

Comment from CEO Yoshiyuki Aikawa “We are delighted to welcome Mr. Shinya Inoue as our new CMO. He brings exceptional ...

Breckenridge Distillery is a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a leading global ...

Bioeq AG is a Swiss biopharmaceutical joint venture between Polpharma Biologics Group and Formycon AG. Bioeq develops and licenses biosimilars for global markets, combining innovation and quality to ...

UNP’s platform combines AI-guided compound design, massively parallel synthesis, and direct-to-biology screening, enabling the rapid generation of drug-like macrocycles that bind challenging targets ...

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, has exercised its option to license Abeona's ...

Under the terms of the agreement, Sobi will acquire 90% of Apellis’ ex-U.S. royalties for Aspaveli for $275 million in cash. Apellis will also be eligible for up to $25 million in milestone payments ...